- Investing Ideas
- /
- Swiss Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
Swiss Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
Results
2
0 new
Companies with promising cash flow potential yet trading below their fair value, as determined by SWS DCF valuation, signaling opportunity for value-oriented investors.
2 companies
SKAN Group
Market Cap: CHF 1.4b
Provides isolators, cleanroom devices, and decontamination processes for pharmaceutical and chemical industries in Europe, the Americas, Asia, and internationally.
SKAN
CHF 62.80
7D
3.8%
1Y
-19.5%
PolyPeptide Group
Market Cap: CHF 551.0m
Operates as a contract development and manufacturing company in Europe, the United States, and India.
PPGN
CHF 16.70
7D
15.8%
1Y
-42.8%